GFAP and Alzheimer disease: Blood biomarkers present a scalable, accessible, and resource-efficient diagnostic alternative.ObjectiveTo investigate the diagnostic and differential diagnostic performance of three clinically relevant plasma biomarkers: phosphorylated tau-217 (pTau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) for biologically confirmed AD patients in real-world, clinical settings.MethodsA systematic search was conducted across 5 databases for peer-reviewed studies between January 2019-January 2025.